AlzChem Group (ACT0) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of AlzChem Group stock €107, price €162, upside -34.1%, quality 72 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding.
Show moreShow less
The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries.
This segment manufactures composite materials and adhesives, as well as silicon nitride for ceramics; and photovoltaic modules in the solar industry.
The Basics & Intermediates segment produces raw materials for specialty chemicals; and products for agriculture and metallurgy, as well as intermediates for the chemical industry that are produced from lime, carbon, and electricity.
This segment also engages in the production and sale of guanidine salts as a raw material for agrochemicals and active pharmaceutical ingredients.
The Other & Holding segment provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services.
It offers products and services to agricultural sector under the CALCIUM CYANAMIDE PERLKA, EMINEX, DORMEX, ALZOGUR, SITOFEX, and BREAK-THRU brands; animal nutrition sector under the CREAMINO brands; human nutrition sector under the CREAPURE, CREAVITALIS, LIVADUR, and ALIPURE brands; pharma sector under the GUANIDINE SALTS " BIOSELECT brand; fine chemicals sector under the GUANIDINSALZE -BIOSELECT, CYANAMIDE, DICYANDIAMIDE, GUANAMINE, NITRILES, MELFLOCK and ALZOFIX, THIOUREA, and NITROGUANIDINE brands; metallurgy sector under the CAD, CALCIPRO, and CALZOT brands, as well as technical gases and calcium carbide; renewable energy sector under the DYHARD and SILZOT brands; and custom synthesis, such as toll micronization and manufacturing.
AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.
Stock analysis
AlzChem Group (ACT0) currently trades at €161.60, while our model-based Fair Value estimate is €106.56, 34.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €137.09 per share, and 2 of the 23 models we run sit above the €161.60 price.
Bear case: the Asset-Based group reads lowest at €16.96, and 21 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: €79.92 (bear) to €133.20 (bull), the price of €161.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
AlzChem Group reported revenue of €562M in FY2025 versus €542M in FY2022, a compound +1.2%/yr. Reported net income was €63.5M in FY2025, compounding +28.3%/yr from FY2022.
Key figures
Market cap €1.6B Small · P/E ratio 24.1 · P/S ratio 2.76 · EPS (TTM) €6.70 · Dividend yield 1.3% · Net margin 11.4% · Return on equity 27.7% · Return on assets (EBIT) 12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (low confidence).
What moves the price
For context, the median of 10 Basic Materials peers we cover trades at −44% fair-value upside, at −34%, ACT0 screens cheaper than that median.
Fair Value models
Bear€79.92Fair Value €106.56Bull€133.20
Price €161.60 · Upside -34.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€3.82 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+32.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+31.2%
Dividend (yield on the price)1.3%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 17%
2025 sits 84% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −2.5% a year for the price and +9.9% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 720 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside−34.1% · Below median
Profitability
Return on equity (12 months)27.7% · Top 25%
Return on assets10.3% · Top 25%
Net margin (12 months)11.4% · Top 25%
Operating margin (12 months)14.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)9.0% · Below median
Dividend yield (12 months)1.3% · Below median
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (12 months)24.1× · Pricier than median
P/B6.38× · Priciest 25%
P/S (12 months)2.76× · Pricier than median
Price / free cash flow11.9× · Cheaper than median
EV/EBITDA13.5× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)45· sector 65
PAST (return on equity)100· sector 27
HEALTH (low debt)93· sector 95
DIVIDEND (yield)26· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AlzChem Group Fair Value". https://www.fairvalue-calculator.com/stock/ACT0
Frequently asked questions
Is AlzChem Group (ACT0) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of €106.56 versus a price of €161.60, about −34% upside (overvalued).
What is the fair value of ACT0?
Our model-based fair value for AlzChem Group is €106.56 (as of Oct 30, 2026), built from audited fundamentals. The current price: €161.60.
What is the quality score of ACT0?
AlzChem Group has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AlzChem Group (ACT0)?
Our model-based price target is the fair value of €106.56 (as of Oct 30, 2026) from 23 valuation models. Cautious scenario €79.92, optimistic scenario €133.20. It is a calculation from audited fundamentals, not an analyst target.
What is the AlzChem Group stock forecast for 2026?
Our models put fair value at €106.56, about −34% upside versus a price of €161.60 (overvalued). Cautious scenario €79.92, optimistic scenario €133.20. The calculation is refreshed regularly with new filings.
What is the revenue of AlzChem Group (ACT0)?
AlzChem Group reported trailing-twelve-month revenue of about €594M (latest available figure, as of Oct 30, 2026).
Does AlzChem Group pay a dividend?
AlzChem Group currently shows a dividend yield of 1.30% relative to its recent price (as of Oct 30, 2026).
What growth is priced into AlzChem Group (ACT0)?
For today's price to be fair in a discounted-cash-flow model, AlzChem Group would have to grow free cash flow by -0.4 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +1.2 % per year. As of Oct 30, 2026.
What discount rate (WACC) does the fair value of ACT0 use?
Our models discount AlzChem Group at 9.6 %: a base by market capitalisation (small), damped by beta 0.38, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AlzChem Group that is -0.4 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has AlzChem Group (ACT0) delivered so far?
Over the past 3 years revenue at AlzChem Group grew +1.2 % a year. The price currently implies -0.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AlzChem Group (ACT0) growing?
The median revenue growth in the sector is +11.3 % a year. That is the yardstick for the growth priced into AlzChem Group (-0.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AlzChem Group (ACT0)?
The free-cash-flow yield on the price is 8.37 %: that much free cash flow AlzChem Group produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AlzChem Group (ACT0)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AlzChem Group it is €106.56 per share (as of Oct 30, 2026), against a price of €161.60. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is AlzChem Group stock overvalued or undervalued in 2026?
As of Oct 30, 2026, ACT0 trades above its calculated fair value: price €161.60, fair value €106.56, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACT0?
No. The price is what the market pays today (€161.60); the fair value is what the company's own numbers justify (€106.56). For AlzChem Group the two are €55.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is AlzChem Group worth?
The market values AlzChem Group at about €1.6B (market capitalisation, as of Oct 30, 2026). Per share that is €161.60; our models calculate a fair value of €106.56 per share.
What do the bullish and bearish scenarios say about ACT0?
Our models span a range for AlzChem Group: cautious scenario €79.92, base €106.56, optimistic €133.20 per share (as of Oct 30, 2026, price €161.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ACT0?
AlzChem Group trades at a price-to-earnings ratio of 24.1 (as of Oct 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €106.56 is built from several models across several years. Other multiples: P/B 6.4, P/S 2.8, EV/EBITDA 13.5.
How solid is the balance sheet of AlzChem Group (ACT0)?
Balance-sheet figures for AlzChem Group (as of Oct 30, 2026): return on equity 27.7%, debt of 0.14 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
Which stocks are comparable to AlzChem Group?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AlzChem Group stock attractive at the current price?
The data as of Oct 30, 2026: price €161.60, calculated fair value €106.56 (−34%), Quality Score 72/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACT0 calculated?
We run AlzChem Group through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €106.56, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. AlzChem Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AlzChem Group (ACT0)?
The closing price on Oct 29, 2026 was €161.60. Our model-based fair value is €106.56, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AlzChem Group right now?
A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (€133.20). The favourable scenario is already priced in.
Key figures of AlzChem Group
How large is the market capitalisation of AlzChem Group (ACT0)?
The market capitalisation of AlzChem Group is €1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AlzChem Group (ACT0)?
The price-to-sales ratio of AlzChem Group is 2.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AlzChem Group (ACT0)?
Earnings per share at AlzChem Group are €6.70 (price ÷ EPS = P/E 24.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AlzChem Group (ACT0)?
The dividend yield of AlzChem Group is 1.3% (payout 31.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AlzChem Group (ACT0)?
The net margin of AlzChem Group is 11.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AlzChem Group (ACT0)?
The return on equity (ROE) of AlzChem Group is 27.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AlzChem Group (ACT0)?
On an EBIT basis the return on assets of AlzChem Group is 12.9% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AlzChem Group (ACT0)?
The operating margin of AlzChem Group is 14.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AlzChem Group (ACT0)?
Revenue at AlzChem Group is growing +9.0% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AlzChem Group (ACT0)?
Earnings per share at AlzChem Group are growing +5.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch AlzChem Group in the live analysis
One click puts AlzChem Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 30, 2026